Treatment of patients with coronary artery disease with biodegradable polymer based paclitaxel-eluting Infinnium coronary stent system: results of 1-year clinical follow-up a single center experience.
Evaluating the efficacy of the Infinnium paclitaxel-eluting coronary stent system with the biodegradable polymer in the treatment of symptomatic coronary artery disease. Total 153 patients were treated with native coronary artery lesion treated with Infinnium paclitaxel-eluting coronary stent system. This study was a single centre, non-randomized, retrospective study. At baseline diabetes, hypertension and smoker patients were present in 53 (35%), 112 (73%) and 80 (52%) respectively. The number of patients with unstable angina and acute MI on admission was 48 (31%) and 7 (5%) respectively. Patients with left ventricular ejection fraction less than 40% were 18 of the study population. Clinical information was collected 1, 3, 6 and 12 months after procedure. Major adverse cardiac event was defined as death, non-fatal myocardial infarction and target vessel revascularization (TVR). Cumulative MACE rates were 5 (3.3%) in first month, 6 (3.9%) in 3 months, 9 (5.9%) in 6 months and 15 (9.8%) in 1-year. At the end of 1-year follow-up period, TVR was 7.8% (12 Patients), which included 8 (5.2%) PCI and 4 (2.6%) CABG Patients. 1-year survival without MACE was 90.2 % This study demonstrates that the Infinnium paclitaxel-eluting coronary stent system with the biodegradable polymer in the treatment of symptomatic coronary artery disease is a concurrent with current standard of treatment.